Literature DB >> 12927514

Phospholipase A2 expression in tumours: a target for therapeutic intervention?

Jonathan P Laye1, Jason H Gill.   

Abstract

Phospholipase A(2) (PLA(2)) enzymes are involved in lipid metabolism and, as such, are central to several cellular processes. The different PLA(2)s identified to date can be classified into three groups: secreted PLA(2) (sPLA(2)), calcium-independent PLA(2) (iPLA(2)) and calcium-dependent cytosolic PLA(2) (cPLA(2)). In addition to their role in cellular signalling, PLA(2)s have been implicated in diverse pathological conditions, including inflammation, tissue repair and cancer. Elevated levels of sPLA(2) and cPLA(2) have been reported in several tumour types. Here, we summarize the current views on the PLA(2)s, and look at their expression, role in human malignancy and potential as targets for anticancer drug development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927514     DOI: 10.1016/s1359-6446(03)02754-5

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  31 in total

1.  Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells.

Authors:  Shenbagamoorthy Sundarraj; Soundarapandian Kannan; Ramar Thangam; Palani Gunasekaran
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-25       Impact factor: 4.553

Review 2.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

3.  Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia?

Authors:  Mario Menschikowski; Albert Hagelgans; Susanne Fuessel; Olga A Mareninova; Volker Neumeister; Manfred P Wirth; Gabriele Siegert
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

4.  Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.

Authors:  Mindy Porterfield; Peng Zhao; Haiyong Han; John Cunningham; Kazuhiro Aoki; Daniel D Von Hoff; Michael J Demeure; J Michael Pierce; Michael Tiemeyer; Lance Wells
Journal:  J Proteome Res       Date:  2013-12-12       Impact factor: 4.466

5.  Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Heike Kostka; Graeme Eisenhofer; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

6.  Molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions.

Authors:  Lars Linderoth; Thomas L Andresen; Kent Jørgensen; Robert Madsen; Günther H Peters
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

7.  Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci.

Authors:  Marianne Berg; Trude H Agesen; Espen Thiis-Evensen; Marianne A Merok; Manuel R Teixeira; Morten H Vatn; Arild Nesbakken; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2010-05-06       Impact factor: 27.401

8.  Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma.

Authors:  A W L Bayci; D A Baker; A E Somerset; O Turkoglu; Z Hothem; R E Callahan; R Mandal; B Han; T Bjorndahl; D Wishart; R Bahado-Singh; S F Graham; R Keidan
Journal:  Metabolomics       Date:  2018-08-03       Impact factor: 4.290

Review 9.  Environmentally responsive peptides as anticancer drug carriers.

Authors:  Suhaas Aluri; Siti M Janib; J Andrew Mackay
Journal:  Adv Drug Deliv Rev       Date:  2009-07-20       Impact factor: 15.470

10.  Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.

Authors:  Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.